Financing
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE
Halozyme Therapeutics
PR-09-24-NI-31Oct 04, 2024
Collaboration
ViiV Healthcare and Halozyme Enter Global Collaboration for ENHANZE® Drug Delivery Technology to Enable Development of “Ultra Long-Acting” Medicines for HIV
GSK
PR-M06-21-032Jun 25, 2021
Restructuring
Halozyme Announces Actions To Focus Strategy On ENHANZE® Drug Delivery Technology
Halozyme Therapeutics
PR-M11-19-NI-009-1975Nov 08, 2019
Licensing
argenx Licenses Halozyme Subcutaneous Delivery Tech
Nice Insight
PAO-M02-19-NI-002Feb 05, 2019
Clinical Trials
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE® Technology
Halozyme Therapeutics
PR-M07-18-NI-106Jul 31, 2018